Expand NUVB Menu
NUVB MENU

NUVB Latest Press Releases

-- March 26, 2026 --

Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency PRNewswire 4:05 PM

-- March 21, 2026 --

NUVB Investors Have Opportunity to Join Nuvation Bio Inc. Fraud Investigation with the Schall Law Firm Business Wire 5:15 PM

-- March 17, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nuvation Bio Inc. - NUVB Globe Newswire 5:33 PM
Nuvation Bio to Present Pivotal IBTROZI (Taletrectinib) Data in TKI-Nave and TKI-Pretreated Patients with Advanced ROS1-Positive Non-Small Cell Lung Cancer at AACR 2026 PRNewswire 4:35 PM

-- March 13, 2026 --

Kuehn Law Encourages Investors of Nuvation Bio Inc. to Contact Law Firm Globe Newswire 9:12 AM

-- March 12, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nuvation Bio Inc. - NUVB PRNewswire 10:00 AM

-- March 10, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nuvation Bio Inc. - NUVB Globe Newswire 4:03 PM

-- March 6, 2026 --

Kuehn Law Encourages Investors of Nuvation Bio Inc. to Contact Law Firm PRNewswire 2:21 PM

-- March 4, 2026 --

Nuvation Bio Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses Globe Newswire 8:30 AM

-- March 2, 2026 --

Nuvation Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update PRNewswire 4:05 PM

-- February 25, 2026 --

Nuvation Bio to Participate in Upcoming Investor Conferences PRNewswire 4:05 PM

-- February 17, 2026 --

Nuvation Bio to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 2, 2026 PRNewswire 4:05 PM

-- February 9, 2026 --

Nuvation Bio Announces Pivotal Global Phase 3 SIGMA Trial (G203) for Safusidenib in IDH1-Mutant Glioma Business Wire 8:00 AM

-- January 12, 2026 --

Nuvation Bio Reports Preliminary Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook Ahead of 44th Annual J.P. Morgan Healthcare Conference Business Wire 8:00 AM
Nuvation Bio and Eisai Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside U.S., China and Japan Business Wire 7:30 AM

-- January 6, 2026 --

Nuvation Bio to Present at the 44th Annual J.P. Morgan Healthcare Conference Business Wire 4:05 PM

-- December 6, 2025 --

Innovent Announces Inclusion of Seven Innovative Drugs including TYVYT New Indication and SYCUME in China's National Reimbursement Drug List PRNewswire 10:40 PM

-- December 3, 2025 --

Nuvation Bio Announces Publication of Positive Phase 2 Study Results for Safusidenib for the Treatment of Grade 2 IDH1-Mutant Glioma in Neuro-Oncology Business Wire 8:00 AM

-- November 26, 2025 --

Nuvation Bio to Participate in Upcoming Investor Conferences Business Wire 4:05 PM

-- November 3, 2025 --

Nuvation Bio Reports Third Quarter 2025 Financial Results and Provides Business Update Business Wire 4:05 PM
Market Data Delayed 15 Minutes